Modafinil and pregnancy

This page is a reference summary of published evidence and regulatory documents. It is not a substitute for individual medical advice, and it is not a recommendation to take or avoid any medicine.

Medically reviewed by Dr. Sofia Lindqvist, · Last reviewed 11 August 2026

Modafinil is contraindicated in pregnancy in the European Union following a 2019 EMA review that found a higher-than-background rate of major congenital malformations in exposed pregnancies. The US label carries no equivalent contraindication, an unusual and clinically important divergence between regulators reviewing the same underlying data.

A second, separate issue compounds this: modafinil reduces the effectiveness of hormonal contraception, which means unplanned exposure in early pregnancy is more likely than the label alone would suggest.

The evidence: registry and cohort data

The main data source is a pregnancy registry run by Cephalon (modafinil’s original manufacturer) and later reviewed by European and North American regulators, supplemented by Nordic and US claims-based cohort studies. The registry recorded 78 reported pregnancies with modafinil exposure, of which 61 had known outcomes.

Among those 61 outcomes, 9 major congenital malformations were reported — a rate of approximately 15%. Background rates of major congenital malformation in the general population are approximately 3%. The malformations reported were not a single pattern but included congenital torticollis, hypospadias, and congenital heart defects.

The registry is small, was not randomised, and pregnancies that are voluntarily reported to a manufacturer registry may differ from the general population of exposed pregnancies in ways that are hard to quantify. Even so, a fivefold difference from background prompted regulatory action rather than being dismissed as noise.

International regulatory timeline

Regulator	Jurisdiction	Action	Year
EMA (PRAC)	European Union	Review concluded modafinil should be contraindicated in pregnancy	2019
Health Canada	Canada	Safety review of modafinil and pregnancy outcomes	2019
MHRA	United Kingdom	Drug Safety Update advising against use in pregnancy	2019
TGA	Australia	Product information updated to reflect malformation risk	2019–2020
HPRA	Ireland	Aligned with EMA contraindication	2019

Dates reflect published regulatory actions; consult each regulator’s current product information for the operative text.

The US position and the Public Citizen petition

The FDA-approved US label describes the pregnancy registry findings in narrative form but does not contain a contraindication; it leaves the risk-benefit decision to the prescriber and patient. This is a materially different regulatory posture from the EU’s, despite both being informed by the same registry.

The advocacy group Public Citizen has petitioned the FDA to strengthen the modafinil label, arguing that the agency’s position understates the malformation signal relative to EMA’s conclusion. As of this review, the FDA has not added a contraindication.

The contraceptive interaction

Modafinil induces the hepatic enzyme CYP3A4, which metabolises ethinyl estradiol, the estrogen component of most combined oral contraceptives. This induction increases ethinyl estradiol clearance by approximately 18%, lowering circulating hormone levels and reducing contraceptive reliability.

Because CYP3A4 induction persists after a drug is stopped while enzyme levels return to baseline, prescribing information advises using a non-hormonal or additional contraceptive method during modafinil treatment and for two months after discontinuation.

Why these two findings compound

Compounding risk

Reduced contraceptive reliability and an elevated malformation rate are two separate findings that interact in practice. A contraceptive failure during modafinil treatment is more likely than usual, and if it results in pregnancy, that pregnancy carries the elevated malformation risk described above. Neither fact alone explains the other; taken together they are the basis for the EU contraindication.

What it means for women of childbearing potential

Anyone taking modafinil who could become pregnant should use a non-hormonal or additional contraceptive method, and should discuss pregnancy plans with a prescriber before continuing or starting treatment.

If pregnancy occurs or is suspected while taking modafinil, that should be reported to a prescriber promptly so that continuation, discontinuation and monitoring can be discussed individually. This page does not make that decision; it describes the evidence a prescriber uses to help make it.

Frequently asked questions

Is modafinil safe in pregnancy?

Registry data show a higher rate of major congenital malformations than background — around 15% versus roughly 3% — so modafinil is not considered safe in pregnancy and is contraindicated in the EU.

Why does the US label differ from the EU label?

The FDA has not added a contraindication; the label carries narrative pregnancy-risk information but leaves the prescribing decision to the clinician, while EMA’s PRAC concluded the risk warranted an outright contraindication in 2019.

Does modafinil affect birth control pills?

Yes. Modafinil induces CYP3A4, which increases clearance of ethinyl estradiol by around 18%, reducing hormonal contraceptive reliability during use and for two months after stopping.

What malformations were reported in the registry?

The Cephalon-sponsored pregnancy registry recorded 9 major congenital malformations among 61 known outcomes from 78 reported pregnancies, including congenital torticollis, hypospadias and congenital heart defects.

What should someone who could become pregnant do?

Use a non-hormonal or additional contraceptive method while taking modafinil and for two months afterward, and discuss any pregnancy plans with a prescriber before continuing treatment.